{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stensland KD"],"funding":["NCI","NCI NIH HHS"],"pagination":["135-141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11229680"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["184"],"pubmed_abstract":["<h4>Objective</h4>To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer.<h4>Methods</h4>We conducted a retrospective study of men with localized prostate cancer treated with radical prostatectomy from 2005 to 2015 with follow-up through 2019 in the Veterans Health Administration. We defined biochemical recurrence (BCR) as a prostate-specific antigen ≥0.2 ng/mL. We used a validated natural language processing encoded dataset to identify incident metastatic prostate cancer. We estimated overall survival from time of surgery, time of BCR, and time of first metastasis using the Kaplan-Meier method. We then estimated time from surgery to BCR, BCR "],"journal":["Urology"],"pubmed_title":["National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer."],"pmcid":["PMC11229680"],"funding_grant_id":["U01 CA253915","R01 CA242559","F32 CA264874"],"pubmed_authors":["Stensland KD","Shin C","Burns JA","Sparks JB","Tsodikov A","Skolarus TA","Hollenbeck BK","Caram MEV","Elliott DA","Zaslavsky A","Herr DJ","Morgan TM"],"additional_accession":[]},"is_claimable":false,"name":"National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer.","description":"<h4>Objective</h4>To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer.<h4>Methods</h4>We conducted a retrospective study of men with localized prostate cancer treated with radical prostatectomy from 2005 to 2015 with follow-up through 2019 in the Veterans Health Administration. We defined biochemical recurrence (BCR) as a prostate-specific antigen ≥0.2 ng/mL. We used a validated natural language processing encoded dataset to identify incident metastatic prostate cancer. We estimated overall survival from time of surgery, time of BCR, and time of first metastasis using the Kaplan-Meier method. We then estimated time from surgery to BCR, BCR ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-21T23:51:50.018Z","creation":"2025-04-05T19:19:35.145Z"},"accession":"S-EPMC11229680","cross_references":{"pubmed":["37951360"],"doi":["10.1016/j.urology.2023.10.018"]}}